About this episode

Larry Luxner interviews Dr. Andrew Wilson about therapies for alpha-1 antitrypsin deficiency.

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Andrew Wilson, MD, scientific director of the Alpha-1 Foundation, about the latest therapies to treat alpha-1 antitrypsin deficiency, an incurable genetic disease that causes both lung and liver damage.

People in this episode

Host: Larry Luxner

Guest: Andrew Wilson

Topics covered

• alpha-1 antitrypsin deficiency
• genetic disease
• lung damage
• liver damage
• therapies
• interview

Keywords

• alpha-1 antitrypsin deficiency
• genetic disease
• lung damage
• liver damage
• therapies
• interview

Mentioned in this episode

Organizations: Alpha-1 Foundation, Rare Disease Advisor

More episodes of Rare Care Podcast

• An Interview With Dr. Michelle Ng Gong, New President of the American Thoracic Society · June 9, 2026 · 11 min
• An Interview With Dr. Vallerie McLoughlin, Director of the University of Michigan's Pulmonary Hypertension Program · May 26, 2026 · 9 min
• An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator · May 18, 2026 · 15 min
• An Interview With Henriette Farkas, Director of the Hungarian Angioedema Reference Center in Budapest · May 14, 2026 · 13 min

Explore listener stats, chart rankings, contacts and more on the Rare Care Podcast podcast page.